Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients (GIEU006)
HIV Infection
About this trial
This is an interventional treatment trial for HIV Infection focused on measuring HIV, Vaccine, Immune Therapy, DermaVir
Eligibility Criteria
Main inclusion Criteria:
- HIV antibody positive
- Plasma HIV RNA value ≥5,000 copies/mL and ≤ 150,000 c/mL
- Antiretroviral therapy naïve
- Documented CD4+ T-cell count at screening ≥400 cells/mm3
Main exclusion Criteria:
- No skin disease
- No tattoos, or changes in pigmentation at the selected skin immunization sites
- No acute or chronic illness (e.g Hepatitis C)
- No chronic autoimmune diseases
- No treatment with any immune modulating agents
Sites / Locations
- ifi-Medizin GmbH at the Asklepios Klinik St. Georg
- ICH Grindel
- University Medical Center Hamburg-Eppendorf
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
1: Low dose DermaVir
2: Low dose Placebo
3: Medium dose DermaVir
4: Medium dose Placebo
5: High dose DermaVir
6: High dose Placebo
Dosage: 0.2 mg DNA Dosage form: 1.6 mL DNA/PEIm nanomedicine Administration with 2 DermaPrep patches Frequency: every six weeks Duration: 18 weeks (4 DermaVir treatments)
Dosage form: 1.6 mL Placebo Administration with 2 DermaPrep patches Frequency: every six weeks Duration: 18 weeks (4 Placebo treatments)
Dosage: 0.4 mg DNA Dosage form: 3.2 mL DNA/PEIm nanomedicine Administration with 4 DermaPrep patches Frequency: every six weeks Duration: 18 weeks (4 DermaVir treatments)
Dosage form: 1.6 mL Placebo Administration with 4 DermaPrep patches Frequency: every six weeks Duration: 18 weeks (4 Placebo treatments)
Dosage: 0.8 mg DNA Dosage form: 6.4 mL DNA/PEIm nanomedicine Administration with 8 DermaPrep patches Frequency: every six weeks Duration: 18 weeks (4 DermaVir treatments)
Dosage form: 6.4 mL Placebo Administration with 8 DermaPrep patches Frequency: every six weeks Duration: 18 weeks (4 Placebo treatments)